

# Opportunistic intestinal parasitic infections in patients with HIV/AIDS in Iran: a systematic review

Soghra Viesy<sup>1</sup>, Amin Jaydari<sup>2</sup>, Arya Abbassioun<sup>3</sup>, Iman Pouladi<sup>3</sup>

<sup>1</sup>Department of Parasitology, Faculty of Paramedicine, Ilam University of Medical Sciences, Ilam, Iran

<sup>2</sup>Department of Microbiology and Food Hygiene, Faculty of Veterinary Medicine, Lorestan University, Khorramabad, Iran

<sup>3</sup>Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran

## Abstract

At present, acquired immunodeficiency syndrome (AIDS) is one of the biggest and most mortal infectious diseases worldwide in distribution, while human immunodeficiency virus (HIV) cases increase each year. Opportunistic infections are among the major health problems affecting HIV/AIDS patients worldwide, usually following an increase in immunosuppression, which occurs mainly in late stages of disease. Immunosuppression is also known to expose HIV-positive patients to a wide range of parasitic and microbial infections. Intestinal parasitic infections cause severe problems in patients infected with HIV. There have been reports of intestinal parasitic infections in HIV/AIDS patients from different regions of Iran, and the most common species are *Giardia lamblia*, *Blastocystis hominis*, and *Cryptosporidium*. The impact of intestinal parasite infections on immunocompromised patients has been studied extensively worldwide, but few comparable studies have been conducted in Iran. Iran's HIV/AIDS situation is suspected to be more serious than previously thought, with the main concern being the spread of the disease from injecting drug addicts to the young population through risky sexual behaviors. In Iran, intestinal parasite infections remain a major health concern, with the World Health Organization estimating that 3.5 billion people are affected by intestinal parasitic infections worldwide.

HIV AIDS Rev 2026; 25, 1: ?-?  
DOI: <https://doi.org/10.5114/hivar/169665>

**Key words:** intestinal parasitic infections, HIV/AIDS, Iran.

## Introduction

At present, acquired immunodeficiency syndrome (AIDS) is one of the biggest and most mortal infectious diseases worldwide in distribution [1, 2]. According to a joint report of the World Health Organization (WHO) and the United Nations Program on HIV/AIDS, by the end of 2019, approximately 38 million people worldwide were living with HIV, of whom more than 1 million died due to HIV-related

diseases [3, 4]. AIDS patients are at higher risk of many diseases, including various types of infectious diseases [2]. Usually, due to following elevated immunosuppression that mainly happens in the late phase of the disease, opportunistic infections are among the main health problems influencing HIV/AIDS patients globally. Such immunosuppression most typically exposes HIV patients to an extensive confine of parasitic and microbial attacks [3]. Intestinal parasitic

**Address for correspondence:** Iman Pouladi,  
Department of Microbiology and Immunology,  
Faculty of Veterinary Medicine, University of Tehran,  
Gharib Street, 1419963111, Iran,  
e-mail: imanpouladi96a@gmail.com

**Article history:**  
Received: 12.02.2023  
Revised: 16.07.2023  
Accepted: 16.07.2023  
Available online: 30.01.2026



infections cause very serious problems in HIV-infected patients. In AIDS patients, opportunistic gastrointestinal infections cause serious complications, such as severe diarrhea, and seriously affect the small intestinal absorption function, leading to remarkable mortality [2, 5]. Intestinal parasitic infections have been identified as one of the leading causes of disease and the most common infections of human beings worldwide [6, 7]. Nowadays, the burden of intestinal parasitic infections (IPIs) is estimated to be around three billion in the world population [6]. Intestinal parasitic infections are one of the leading causes of death worldwide in developing countries, and this threat has increased dramatically [8]. The menace has been noticeably elevated with the coexistence of large load of HIV/AIDS and undernourishment in the area. Moreover, intestinal parasites are extremely relevant to the extension and development of HIV/AIDS. The vastness of intestinal parasitic infections is highest in sub-Saharan African countries, where the maximum proportions of HIV/AIDS cases are located. Evidence suggests that HIV-infected patients are the most vulnerable to simultaneous infections, such as parasitic and bacterial ones [9-12]. Opportunistic intestinal parasitic infections that coexist with HIV in people are *Cryptosporidium* and *Isospora belli*, while the most common non-opportunistic parasitic infections in people living with HIV/AIDS in low-income as well as middle-income countries are *Entamoeba histolytica* and *Giardia lamblia* [13, 14]. Different evidence showed that diarrhea occurs in 30-60%

of HIV-infected patients in developed countries, while in low and middle-income countries, about 90% of HIV patients are affected by diarrhea resulting mostly from intestinal parasitic infections [15]. Studies conducted in different countries demonstrate that the extent of intestinal parasitic infections amongst HIV/AIDS patients has been diverse between countries. Moreover, the prevalence of intestinal parasitic infections amongst HIV/AIDS patients was 17% in France, 40% in Brazil, 48.8% in Iran, and 69% in Mexico. Similarly in Africa, the magnitude of IPIs amongst HIV/AIDS patients was 57.48% in Cameroon, 24.7% in Nigeria, 65.3% in Burkina Faso, and 50.9% in Kenya [8]. In spite of recent increases in the number of HIV-infected patients in Iran, little attention has been paid to the opportunistic parasitic infections among these patients. Therefore, the aim of this study was to investigate the trend of parasitic intestinal infections in AIDS patients in Iran.

## Material and methods

### Search strategy and data extraction

MEDLINE search, included PubMed, Scopus, Science Direct, Web of Science (ISI), Google Scholar as English databases as well as Magiran, Iran Medex, Iran Doc, and SID as Persian databases, using the following terms: "Intestinal Parasitic Infections", "*Giardia lamblia*", "*Cryptosporidium*", "*Enterobius vermicularis* (oxyure)", "*Isospora belli*", "*Ascaris lumbricoides*", "*Entamoeba histolytica*", "HIV", "AIDS", "Iran".

An extensive search of published and unpublished articles as well as abstracts and summaries of parasitology congresses, was conducted to gather precise information. English and Persian articles were consulted for data collection, with protocol for data extraction defined and assessed independently.


### Study selection and identification

As shown in Figure 1, 215 articles were searched and identified on the prevalence and factors associated with intestinal parasitic infections among HIV/AIDS patients in Iran. After removing 60 duplicates, a total of 155 studies were retrieved, 55 of which were rejected solely based on titles and 78 after reviewing abstracts. Consequently, 65 studies were reviewed based on inclusion and exclusion criteria, and evaluated for eligibility. Ultimately, 21 studies met the eligibility criteria and were included in the final systematic review (Figure 1).

## Results

### Intestinal parasitic infections

Parasitic infections in the gastrointestinal tract remain common among HIV-infected individuals, even when anti-



**Figure 1.** Study selection flow chart of a systematic review of the prevalence and factors associated with intestinal parasitic infections among HIV/AIDS patients in Iran

retroviral drugs are being used. CD4+ count is one of the risk factors for opportunistic parasitic infections, with diarrhea manifestations in HIV patients [16-18]. AIDS patients' intestinal parasites act opportunistically, and severely suppress their immune systems, resulting in fatal diarrheal diseases. Several parasite species can cause diarrhea in HIV patients, including *Cryptosporidium parvum*, *Giardia lamblia*, *Microsporidia*, and *Isospora belli* [19, 20]. It has been reported that *Blastocyst* spp., *Cryptosporidia*, *Strongyloides stercoralis*, *Opisthorchis viverrini*, and *Microsporidia*, are the top intestinal parasites causing diarrhea in HIV patients. In addition, there are parasites known as classical opportunistic agents, which include *Cryptosporidium parvum*, *Isospora belli*, *Cyclospora cayetanensis*, and *Microsporidia* [16].

### Risk factors for opportunistic parasitic infections

There are several risk factors associated with HIV/AIDS, including male gender, unemployment, living in urban areas, and being married. However, other studies have shown that women, housewives, and having business are risk factors for HIV/AIDS. In HIV/AIDS patients, the rate of specific intestinal parasitic infections depends on the endemicity of parasite in the community [21, 22]. Intestinal parasites are widely distributed due to low levels of environmental and personal hygiene, fecal contamination of food and drinking water, and poor housing facilities. In HIV-infected individuals, CD4+ cell counts are helpful for determining parasite infection status. Risk factors associated with a higher prevalence of opportunistic parasitic infections among HIV patients include low CD4+ counts, persistent diarrhea, poor living conditions, and inadequate nutrition [23]. Moreover, previous studies conducted in Ethiopia, India, and Malaysia, have shown a correlation between CD4+ cell count and intestinal protozoan infection. In HIV/AIDS stage, CD4+ count, ART adherence, and hemoglobin level, have also been reported as risk factors for opportunistic parasitic infections. HIV/AIDS patients with fewer than 200 CD4+ cells per microliter were shown to be at the highest risk for opportunistic infections [16, 17, 21].

### *Blastocystis hominis*

As a universal eukaryotic parasite, *Blastocystis hominis* infects a wide variety of animals, including birds, pigs, horses, amphibians, reptiles, and insects [24]. Despite the fact that this protozoan is zoonotic, human beings are its most vulnerable hosts. It is regarded as a pathogenic agent that is primarily responsible for intestinal infections, especially in patients with immunodeficiency [25]. Frequently, it infects the cecum and colon of the intestinal tract, leading to digestive symptoms, such as diarrhea, nausea, abdominal pain, vomiting, and bloating. Generally, the prevalence of *Blastocystis hominis* ranges between 1.6 and 50%. However, in developed countries, the prevalence ranges from 1.5 to

10%, which can cause health deterioration in immunocompromised patients. HIV-positive patients and organ transplant recipients under immunosuppressive treatment can be adversely affected by *Blastocystis hominis* [26]. The prevalence of *Blastocystis hominis* infection in Indonesian individuals with HIV/AIDS amounts to 72% [24]. Researchers in the United States and France have found that the incidence of *Blastocystis hominis* infections is higher in HIV/AIDS patients when compared with *Entamoeba histolytica*, *Giardia lamblia*, and *Cryptosporidium parvum* infections [27].

### *Isospora belli* infections

Research on *Isospora belli*'s role in intestinal infections among immunocompromised patients has been ongoing for many years, and it has been established that while it only causes self-limiting diarrhea in the healthy population, extremely severe symptoms can occur in immunocompromised individuals [28].

### Amoebiasis

Iranian studies suggest that amoebiasis does not occur commonly among the healthy population. Furthermore, with the improvement of public healthcare, this number has decreased significantly over the past few years. Accordingly, it is unlikely that this infection frequently occurs among AIDS patients. In 1975-1976, an Iranian study aiming at diagnosing intestinal parasitic diseases in 35 individuals with AIDS, identified and isolated two parasites, i.e., *Amoeba histolytica* and *Giardia lamblia* [28].

### Cystic echinococcosis/hydatid cyst

HIV, along with other parasitic diseases, may result in serious health problems. There has been a handful of case reports worldwide describing *Echinococcosis* associated with HIV infection. The first case of liver hydatid cyst with concurrent HIV in Iran was found in 2020. Upon reviewing the laboratory report, it was found that the patient was a 46-year-old HIV-positive woman [29]. The disease has been reported in 1% of Iranian patients admitted to surgical departments [30]. In spite of the rarity of cestode-borne parasitic infections in HIV patients, hydatid cysts have been reported in Australia, Turkey, India, Spain, Romania, the Netherlands, Switzerland, and Brazil [31, 32]. Meanwhile, a study by Sharifi *et al.* [29] reported rare cases of hydatid cysts with HIV for the first time in Iran, showing that the cysts were significantly enlarged, which could be due to immune system deficiency. The importance of surgery for patient recovery and survival cannot be overstated.

### Coccidiosis

A coccidial infection is a parasitic disease of the human or animal intestinal tract, caused by coccidial protozoa. Its

primary symptom is diarrhea, which may become bloody in severe cases. Most coccidia infections are asymptomatic, but young or immunocompromised patients can develop severe symptoms or die [33]. There is no accurate estimate of the rate of coccidiosis infection in Iran; cryptosporidiosis, however, has rarely been studied. In previous research, the infection has been detected in 7% of children with diarrhea and 1.5% of HIV-positive patients. Among AIDS patients, an infection rate of 2.3% has been reported [34, 35]. *Cyclospora cayotensis* is an opportunistic protozoan associated with disease outbreaks and endemic areas, causing chronic diarrhea in immunocompromised individuals. It seems that the non-identification of this intestinal coccidian parasite in this study is due to its rare distribution in Iran, as only two cases have been reported so far [34, 36]. *Giardia lamblia* is not considered to be an opportunistic agent compared with other intestinal coccidian parasites, and has rarely been reported to cause severe illnesses among HIV/AIDS-positive patients [34]. The parasite has spread globally, and its prevalence rate is highest in developed and developing countries, especially in areas with poor health conditions and high population density [37, 38]; its prevalence rate is 2-7% in industrialized countries and 8-30% in developing countries [37-39]. There

are approximately 200 million giardiasis patients in Asia, Africa, and Latin America, and 500,000 new cases are reported annually [40-42]. The incidence of giardiasis ranges from 5 to 43% worldwide, and from 5 to 23% in Iran [37]. Europe and North America have the highest number of outbreaks due to health and surveillance systems [43]. The disease is more likely to affect people with immune system defects, children, and pregnant women [44].

### Microsporidia

As spore-like intracellular pathogens, microsporidia can infect invertebrates and vertebrates, including humans. *Encephalitozoon* spp. and *Enterocytozoon bieneusi* are the leading causes of chronic diarrhea, especially in patients with HIV/AIDS. GenBank's database indicates that microsporidia is more prevalent in 92 countries, including India, China, Russia, and Thailand compared with Syria, Switzerland, and Romania. Among Iran's neighboring countries, including Turkey and Iraq, human infection prevalences have been found at 13.4% and 10.3%, respectively [45-47]. *Enterocytozoon bieneusi* is probably the most common intestinal microsporidian genus among HIV/AIDS-positive patients

**Table 1.** Baseline characteristics of cross-sectional studies included in the meta-analysis of intestinal parasitic infection among HIV/AIDS patients in Iran

No.	Authors	Publication year	Region	Number of patients	Prevalence (%)	References
1	Taherkhani <i>et al.</i>	2007	Kermanshah	75	–	[28]
2	Mohraz <i>et al.</i>	2004	Tehran and Kermanshah	206	18.4	[48]
3	Heydari <i>et al.</i>	2021	Bushehr	201	46.8 (AIDS)	[49]
4	Sharif <i>et al.</i>	2021	Shiraz	1	–	[29]
5	Falahi <i>et al.</i>	2007	Khorramabad	306	22.5	[50]
6	Berenji <i>et al.</i>	2010	Mashhad	31	67.7	[51]
7	Meamar <i>et al.</i>	2007	Tehran	781	11.4	[34]
8	Izadi <i>et al.</i>	2019	Isfahan	52	32.7	[33]
9	Nahrevanian <i>et al.</i>	2006	Tehran	23	–	[52]
10	Adarvishi <i>et al.</i>	2016	Ahvaz	200	48.8	[53]
11	Rasti <i>et al.</i>	2017	Kashan and Qom	20	25.0	[54]
12	Najafi-Asl <i>et al.</i>	2020	Bandar Abbas	133	–	[55]
13	Ghafari <i>et al.</i>	2017	Ahvaz	250	10.8	[56]
14	Mirjalali <i>et al.</i>	2014	Tehran	81	30.8	[57]
15	Izadi <i>et al.</i>	2020	Isfahan, Markazi, Yazd, and Chaharmahale Bakhtiari	87	4.6	[58]
16	Daryani <i>et al.</i>	2009	Mazandaran	64	17.2	[59]
17	Ghobadi <i>et al.</i>	2013	Sanandaj	74	25.7	[60]
18	Ghorbanzadeh <i>et al.</i>	2012	Tehran	71	29.57	[61]
19	Esteghamati <i>et al.</i>	2018	Tehran	80	32.5	[35]
20	Yosefi <i>et al.</i>	2012	Ahvaz	100	30.0	[62]
21	Abdolahi Khabisi <i>et al.</i>	2022	Zahedan	50	24.0	[45]

in Iran. Stool preparation and molecular methods, such as Nested-PCR, can be helpful in detecting intestinal microsporidian infection [45]. Numerous studies have documented the prevalence and abundance of this species in Iran, as presented in Tables 1 and 2.


Based on this study's findings, intestinal parasitic infections have been examined in several Iranian cities (Figure 2), particularly mega-cities, such as Tehran, Ahvaz, Mashhad,

Kermanshah, and Isfahan (Table 1). However, these infections have not been comprehensively studied. Following the findings of the current study, it was established that opportunistic infections in patients with HIV/AIDS, primarily intestinal parasites, warrant special attention and more comprehensive investigation in Iran and other countries.

Individuals diagnosed with AIDS in various Iranian cities are susceptible to a wide variety of parasitic species, accord-

**Table 2.** Analysis of frequency and percentage of IPIs in different studies among HIV/AIDS patients in Iran

No.	Authors	Species	References
1	Taherkhani <i>et al.</i>	<i>Ascaris lumbricoides</i> (1.4%), <i>Entamoeba histolytica</i> (2.7%), <i>Escherichia coli</i> (17.4%), <i>Blastocystis hominis</i> (8%), <i>Giardia lamblia</i> (1.4%), <i>Isoospora belli</i> (2.7%), <i>Endolimax nana</i> (2.7%)	[28]
2	Mohraz <i>et al.</i>	<i>Blastocystis hominis</i> (4.4%), <i>Giardia lamblia</i> (7.3%), <i>Cryptosporidium parvum</i> (1.5%), <i>Escherichia coli</i> (3.9%), <i>Strongyloides stercoralis</i> , <i>Hymenolepis nana</i> , <i>Dicrocoelium dendriticum</i>	[48]
3	Heydari <i>et al.</i>	<i>Isoospora</i> spp., <i>Cryptosporidium</i> spp., <i>Sarcocystis</i> spp.	[49]
4	Sharif <i>et al.</i>	Cystic echinococcosis, hydatid cyst	[29]
5	Falahi <i>et al.</i>	<i>Blastocystis hominis</i> (19.2%), <i>Giardia lamblia</i> (34.2%), <i>Cryptosporidium parvum</i> (8.2%), <i>Escherichia coli</i> (16.4%), <i>Strongyloides stercoralis</i> (1.4%), <i>Hymenolepis nana</i> (5.5%), <i>Iodamoeba butschlii</i> (5.5%), <i>Microsporidia</i> spp. (5.5%), <i>Taenia</i> eggs (1.4%)	[50]
6	Berenji <i>et al.</i>	<i>Blastocystis hominis</i> (22.6%), <i>Giardia lamblia</i> (22.6%), <i>Chilomastix mesnili</i> (22.6%), <i>Escherichia coli</i> (9.7%), <i>Enteromonas</i> (3.2%)	[51]
7	Meamar <i>et al.</i>	<i>Blastocystis hominis</i> (6.1%), <i>Giardia lamblia</i> (4.2%), <i>Cryptosporidium parvum</i> (0.9%), <i>Isoospora belli</i> (0.26%), <i>Strongyloides stercoralis</i> (0.26%), <i>Hymenolepis nana</i> (0.13%)	[34]
8	Izadi <i>et al.</i>	<i>Blastocystis hominis</i> (30.4%), <i>Cryptosporidium</i> spp. (3.9%), <i>Escherichia coli</i> (6.3%), <i>Giardia lamblia</i> (5.4%), <i>Endolimax nana</i> (2%), ova of <i>Fasciola</i> spp. (0.5%), <i>Dicrocoelium dendriticum</i> (0.9%)	[33]
9	Nahrevarian <i>et al.</i>	<i>Cryptosporidium</i> spp. (8.7%), <i>Isoospora</i> spp. (4.3%)	[52]
10	Adarvishi <i>et al.</i>	<i>Cryptosporidium</i> (21.3%), <i>Entamoeba histolytica</i> (2.1%), <i>Escherichia coli</i> (6.7%), <i>Blastocystis hominis</i> (10.9%), <i>Giardia lamblia</i> (8.6%), <i>Isoospora belli</i> (0.8%), <i>Endolimax nana</i> (4.4%), <i>Strongyloides stercoralis</i> (0.8%), <i>Hymenolepis nana</i> (1.1%)	[53]
11	Rasti <i>et al.</i>	<i>Blastocystis hominis</i> (15%), <i>Giardia lamblia</i> (5%), <i>Entamoeba histolytica</i> (5%)	[54]
12	Najafi-Asl <i>et al.</i>	<i>Blastocystis hominis</i> (0.8%), <i>Escherichia coli</i> (0.8%), <i>Giardia lamblia</i> (0.8%), <i>Hymenolepis nana</i> (0.8%)	[55]
13	Ghafari <i>et al.</i>	<i>Cryptosporidium parvum</i> (70.38%), <i>Cryptosporidium hominis</i> (25.92%), <i>Cryptosporidium meleagridis</i> (3.7%)	[56]
14	Mirjalali <i>et al.</i>	<i>Enterocytozoon bieneusi</i>	[57]
15	Izadi <i>et al.</i>	<i>Cryptosporidium hominis</i> (91.6%), <i>Cryptosporidium parvum</i> (8.3%)	[58]
16	Daryani <i>et al.</i>	<i>Giardia lamblia</i> (3.1%), <i>Cryptosporidium parvum</i> (9.4%), <i>Escherichia coli</i> (1.6%), <i>Entamoeba histolytica</i> (1.6%)	[59]
17	Ghobadi <i>et al.</i>	<i>Blastocystis hominis</i> (6.8%), <i>Giardia lamblia</i> (1.4%), <i>Cryptosporidium parvum</i> (8%), <i>Escherichia coli</i> (6.8%), <i>Cyclospora cayatanensis</i> (2.7%)	[60]
18	Ghorbanzadeh <i>et al.</i>	<i>Microsporidia</i>	[61]
19	Esteghamati <i>et al.</i>	<i>Blastocystis hominis</i> (16.2%), <i>Giardia lamblia</i> (12.5%), <i>Cryptosporidium</i> (1.2%), <i>Chilomastix mesnili</i> (1.2%), <i>Dientamoeba fragilis</i> (1.2%)	[35]
20	Yosefi <i>et al.</i>	<i>Blastocystis hominis</i> (16.7%), <i>Cryptosporidium parvum</i> (8.3%), <i>Endolimax nana</i> (5%), <i>Escherichia coli</i> (5%), <i>G. intestinalis</i> (3.3%), <i>Entamoeba histolytica</i> cyst (1.7%), <i>Dientamoeba fragilis</i> (1.7%)	[62]
21	Abdolahi Khabisi <i>et al.</i>	<i>Enterocytozoon bieneusi</i> , <i>Encephalitozoon</i> spp.	[45]



**Figure 2.** Based on the cases reported so far, this is a visual representation of the regional distribution of cases in Iran. The vast majority of intestinal parasitic infections reported in people with HIV/AIDS occur in the central, semi-western, southwestern, and southeastern regions of the country

ing to this study. Parasitic species with the highest prevalence and frequency in HIV/AIDS-infected patients in Iran include *Blastocystis hominis*, *Giardia lamblia*, *Cryptosporidium* spp., *Endolimax nana*, and *Entamoeba coli* (Table 2).

The results of our study confirmed that the higher number of cases with intestinal infection caused by opportunistic parasites among persons with low immunity levels, including HIV/AIDS-positive patients, cancer patients, organ transplant recipients, lymphoma, and leukemia patients, is in HIV/AIDS-infected cohort.

## Discussion

Iran reported its first HIV case in 1981, while the first AIDS case was documented six years later in 1987. In 2002, Iran had about 3,000 HIV-positive cases and 400 AIDS cases. In December 2003, 5,780 HIV-positive patients were identified in Iran [3]. HIV infection weakens the host's immune system. Various opportunistic pathogens, such as parasites, can cause severe health problems in an individual and, if not diagnosed and treated on time, can cause severe damage or even lead to the patient's death. Among these opportunistic pathogens, opportunistic parasites, such as toxoplasma, *Cryptosporidium parvum*, *Isospora belli*, *Strongyloides stercoralis*, etc., can be mentioned [50]. Since the reporting of first AIDS cases, several papers have described digestive disorders, notably diarrhea, caused by parasitic infections [33, 50]. IPI appears to be a common health problem among immunocompromised patients in central Iran, according to

some studies. Therefore, these patients should routinely be screened for intestinal parasites and treated promptly if infected. Epidemiological reports from several regions of the world have demonstrated a high prevalence of IPIs among immunocompromised patients [33]. In Iran, however, coccidiosis and other opportunistic parasites are yet to be studied among immunocompromised individuals in terms of their distribution and prevalence [63]. Globally, IPIs are a major public health concern, present in disadvantaged communities to varying degrees. Ethiopia, India, Egypt, Cameroon, Malaysia, Indonesia, China, Iran, Australia, and Turkey, have prevalence rates of 35.8%, 60.5%, 94%, 59.5%, 37.9%, 57.8%, 4.3%, 33.3%, 50%, and 76%, respectively [33]. A developing country in the Middle East, Iran, is still plagued by IPIs in various parts of the country, including Isfahan [33]. According to studies conducted in Tehran and Khorramabad, intestinal parasite prevalence in HIV-positive patients was reported at 18.4% and 19.4%, respectively, indicating a high prevalence of opportunistic gastrointestinal parasites in this population. Therefore, HIV-positive patients require a higher level of care [50, 63]. Cryptosporidiosis and isosporiasis are self-limiting intestinal diseases caused by the protozoan parasites *Cryptosporidium* spp. and *Isospora* spp., respectively. Chronic cryptosporidiosis is responsible for significant morbidity and mortality rates among AIDS patients. A study of Nahrevanian *et al.* [52] was first to report on the simultaneous infection of cryptosporidiosis and isosporiasis in AIDS-infected patients in Iran, and confirmed that out of 23 hospitalized AIDS patients, two cases were infected with *Cryptosporidium* species, one of which was also contaminated with *Isospora* species. As per Ghafari *et al.* study [56] in Iran, cryptosporidiosis was present in 27 out of 250 HIV/AIDS patients (10.8%). Additionally, Srisuphanunt *et al.* [64] conducted a study in urban areas of Thailand to identify *Cryptosporidium* extracted from HIV/AIDS patients using the nested-PCR-RFLP technique. It was found that 18.4% of hospitalized HIV/AIDS patients were infected with cryptosporidiosis. Moreover, high rates of infection among HIV/AIDS patients have been reported in Indonesia (11.9%), India (56.5%), northwestern Ethiopia (43.6%), and Malaysia (12.4%) [56]. Iran has reported the prevalence of cryptosporidium infection among immunocompromised patients at 4.7% in Isfahan, 11.5% in Kashan, 35.9% in Mashhad [15], and 0.9% in Tehran [58]. Differences in the prevalence rate of *Cryptosporidium* species in Iran and other countries may be due to differences in healthcare quality, lifestyle, geographical environment, or methods/protocols used to analyze the prevalence across studies/laboratories [56]. Contrary to a study by Izadi *et al.* [58], the cryptosporidiosis rate in HIV-positive patients was inadequate in Bandar Abbas, 14.9% in Isfahan, and 8.7% in Nehrovanian, Tehran. Furthermore, most studies outside Iran have found a relatively high prevalence of this parasite, especially in developing countries. A study by Mirjalali *et al.* [57] revealed that *Enterocytozoon bienersi* was responsible for the majority of intestinal microsporidia infections in HIV/AIDS-infected patients in Iran. Presently,

no acquired detailed information exist on intestinal microsporidia infection among immunocompromised patients in Iran, except for rare studies, such as those conducted by Agholi *et al.* [65], where some HIV/AIDS-positive patients were found to be infected with microsporidiosis (8/356). Furthermore, no detailed statistics are available on microsporidia infection or the species or genus, which might play a role in the infection transmission cycle among these patients in Iran [57]. Abdi *et al.* study [66] examined 1,708 AIDS patients in 8 Iranian studies, and observed a prevalence rate of 13% for microsporidia among AIDS patients using the PCR method ( $p < 0.001$ ). This study's results indicate that the prevalence of microsporidia among AIDS patients in Iran is 13%, which is in line with the 15% of global average. IPs have been reported in several Iranian regions, with the most common infections being *Giardia lamblia* and *Blastocystis hominis*. Similarly, several groups of immunocompromised patients, including diabetics and patients with HIV/AIDS, exhibited a higher rate. Despite multiple papers on IPs in immunocompromised patients worldwide, only few comparative studies have been conducted in Iran so far [54, 67, 68].

## Conclusions

Iran's HIV/AIDS situation is suspected to be more serious than previously thought, with the main concern being the spread of the disease from injecting drug addicts to the young population through risky sexual behaviors. At present, it is widely recognized that HIV's increasing prevalence in Iran is due in large part to ignorance of HIV transmission methods, prevention factors, and essential life skills. In Iran, intestinal parasite infections remain a major health concern, with the World Health Organization estimating that 3.5 billion people are affected by intestinal parasitic infections worldwide.

## Disclosures

1. Institutional review board statement: Not applicable.
2. Assistance with the article: We tender our apologies to those authors, whose deserving research was not cited in this manuscript.
3. Financial support and sponsorship: None.
4. Conflicts of interest: None.

## References

1. Berenji F, Sarvghad MR, Fata AM, Hosseini Z, Saremi E, Ganjbakhsh M, Izadi Jahanparvar R. A study of the prevalence of intestinal parasitic infection in HIV positive individuals in Mashhad, Northeast Iran. *Jundishapur J Microbiol* 2010; 3: 61-65.
2. Wiwanitkit V. Intestinal parasitic infection in Thai HIV-infected patients with different immunity status. *BMC Gastroenterol* 2001; 1: 3. DOI: 10.1186/1471-230X-1-3.
3. Alemayehu E, Gedefie A, Adamu A, Mohammed J, Kassanew B, Kebede B, et al. Intestinal parasitic infections among HIV-infected patients on antiretroviral therapy attending Debreabor General Hospital, Northern Ethiopia: a cross-sectional study. *HIV AIDS (Auckl)* 2020; 12: 647-655.
4. UNAIDS Report on the Global AIDS Epidemic. Geneva: UNAIDS; 2019.
5. Meamar AR, Rezaian M, Mohraz M, Zahabian F, Hadighi R, Kia EB. A comparative analysis of intestinal parasitic infections between HIV+/AIDS patients and Non-HIV infected individuals. *Iranian J Parasitol* 2007; 2: 1-6.
6. Gedle D, Kumera G, Eshete T, Ketema K, Adugna H, Feyera F. Intestinal parasitic infections and its association with undernutrition and CD4 T cell levels among HIV/AIDS patients on HAART in Butajira, Ethiopia. *J Health Popul Nutr* 2017; 36: 15. DOI: 10.1186/s41043-017-0092-2.
7. Fletcher SM, Stark D, Ellis J. Prevalence of gastrointestinal pathogens in sub-Saharan Africa: systematic review and meta-analysis. *J Public Health Afr* 2011; 2: e30. DOI: 10.4081/jphia.2011.e30.
8. Wondmieneh A, Gedefaw G, Alemnew B, Getie A, Bimerew M, Demis A. Intestinal parasitic infections and associated factors among people living with HIV/AIDS in Ethiopia: a systematic review and meta-analysis. *PLoS One* 2020; 15: e0244887. DOI: 10.1371/journal.pone.0244887.
9. Akinbo FO, Okaka CE, Omoregie R. Prevalence of intestinal parasitic infections among HIV patients in Benin City, Nigeria. *Libyan J Med* 2010; 5: 5506. DOI: 10.3402/ljm.v5i0.5506.
10. Udeh EO, Obiezue RN, Ikele CB, Okoye IC, Otuu CA. Gastrointestinal parasitic infections and immunological status of HIV/AIDS coinfecting individuals in Nigeria. *Ann Glob Health* 2019; 85: 99. DOI: 10.5334/aogh.2554.
11. Bentwich Z, Kalinkovich A, Weisman Z. Immune activation is a dominant factor in the pathogenesis of African AIDS. *Immunol Today* 1995; 16: 187-191.
12. Oteng-Seifah EE. The prevalence of intestinal parasitic infection and their association with the T-cell CD4+ counts of HIV/AIDS infected patients in Kumasi. Thesis submitted to the Department of Clinical Microbiology, Kwame Nkrumah University of Sciences and Technology; 2015.
13. Alemu A, Shiferaw Y, Getnet G, Yalew A, Zelalem A. Opportunistic and other intestinal parasites among HIV/AIDS patients attending Gambi higher clinic in Bahir Dar city, North West Ethiopia. *Asian Pac J Trop Med* 2011; 4: 661-665.
14. Fekadu W, Taye K, Teshome W, Asnake S. Prevalence of parasitic infections in HIV-positive patients in southern Ethiopia: a cross-sectional study. *J Infect Dev Ctries* 2013; 7: 868-872.
15. Olopade BO, Idowu CO. Intestinal parasites among HIV-infected patients at obafemi awolowo university teaching hospitals complex, Ile-Ife. *Ann Trop Pathol* 2017; 8: 34-38.
16. Laksemi DA, Suwanti LT, Mufasirin M, Suastika K, Sudarmaja M. Opportunistic parasitic infections in patients with human immunodeficiency virus/acquired immunodeficiency syndrome: a review. *Veterinary World* 2020; 15: 716-725.
17. Nsagha DS, Njunda AL, Assob NJC, Ayima CW, Tanue EA, Kibu OD, Kwenti TE. Intestinal parasitic infections in relation to CD4+ T cell counts and diarrhea in HIV/AIDS patients with or without antiretroviral therapy in Cameroon. *BMC Infect Dis* 2016; 16: 9. DOI: 10.1186/s12879-016-1337-1.
18. Udeh EO, Obiezue R, Okafor FC, Ikele CB, Okoye IC, Otuu CA. Gastrointestinal parasitic infections and immunological status of HIV/AIDS coinfecting individuals in Nigeria. *Ann Glob Health* 2019; 85: 99. DOI: 10.5334/aogh.2554.
19. Khalil PS, Mirdha BR, Sinha S, Panda S, Singh Y, Joseph A, Deb M. Intestinal parasitosis in relation to anti-retroviral therapy, CD4+ T-cell count and diarrhea in HIV. *Korean J Parasitol* 2015; 53: 705-712.
20. Shilpa HS, Mariraj J. Intestinal parasitic infections in relation to HIV/AIDS status, diarrhoea and CD4 T-cell count. *Int J Curr Microbiol Appl Sci* 2016; 5: 523-531.

21. Solomon FB, Angore BN, Koyra HC, Tufa EG, Berheto TM, Admasu M. Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro zone hospital: a retrospective study. *BMC Res Notes* 2018; 11: 604. DOI: 10.1186/s13104-018-3707-9.
22. Rao RP. Study of opportunistic intestinal parasitic infections in HIV seropositive patients at a tertiary care teaching hospital in Karnataka, India. *Int J Contem Med Res* 2016; 3: 9-22.
23. Kindie Y, Bekele S. Prevalence and risk factors for intestinal parasite infections in HIV/AIDS patients with anti-retroviral treatment in South West Ethiopia. *J Trop Dis* 2016; 4: 3. DOI: 10.4172/2329-891X.1000210.
24. Sadaf HS, Khan SS, Urooj KS, Asma B, Ajmal SM. Blastocystis hominis – potential diarrhoeal agent: a review. *Int Res J Pharm* 2013; 4: 1-5.
25. Angelici MC, Nardis C, Scarpelli R, Ade P. Blastocystis hominis transmission by non-potable water: a case report in Italy. *New Microbiol* 2018; 41: 173-177.
26. Chen CH, Sun HY, Chien HF, Lai HS, Chou NK. Blastocystis hominis infection in a post-cardiotomy patient on extracorporeal membrane oxygenation support: a case report and literature review. *Int J Surg Case Rep* 2014; 5: 637-639.
27. Wawrzyniak I, Poirier P, Viscogliosi E, Dionigia M, Texier C, Delbac F, Alaoui HE. Blastocystis, an unrecognized parasite: an overview of pathogenesis and diagnosis. *Ther Adv Infect Dis* 2013; 1: 167-178.
28. Taherkhani H, Jadidian Kh, Fallah M, Vaziri S. The frequency of intestinal parasites in HIV positive patients admitted to the disease consultation center in Kermanshah Province. *Med Labor J* 2007; 1.
29. Sharifi Y, Sadjjadi SM, Nikoupour Dailami H, Jafari, SH, Anbardar MH, Khosravi MB. Cystic echinococcosis/hydatid cyst coinfection with HIV: a report from Shiraz, Iran. *Can J Gastroenterol Hepatol* 2021; 2021: 8844104. DOI: 10.1155/2021/8844104.
30. Rokni MB. Echinococcosis/hydatidosis in Iran. *Iranian J Parasitol* 2009; 4: 1-16.
31. McCombs SB, Dworkin MS, Wan PCT. Helminth infections in HIV-infected persons in the United States, 1990-1999. *Clin Infect Dis* 2000; 30: 241-242.
32. Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schläpfer E, et al. Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection. *Infection* 2004; 32: 299-302.
33. Izadi S, Ghayour-Najafabadi Z, Yavari M, Mohaghegh MA, Wannigama DL, Moslemzadeh HR, et al. Intestinal parasites associated with opportunistic coccidial infections among immunocompromised individuals in central Iran: a cross sectional study. *Arch Clin Infect Dis* 2019; 14: e79701. DOI: <https://doi.org/10.5812/archcid.79701>.
34. Memar A, Rezaian M, Mohraz M, Zahabioun F, Hadighi R, Kia E. A comparative analysis of intestinal parasitic infections between HIV+/AIDS patients and non-HIV infected individuals. *Iranian J Parasitol* 2007; 2: 1-6.
35. Esteghamati A, Khanaliha K, Bokharaei-Salim F, Sayyahfar S, Ghaaderipour M. Prevalence of intestinal parasitic infection in cancer, organ transplant and primary immunodeficiency patients in Tehran, Iran. *Asian Pac J Cancer Prev* 2019; 20: 495-501.
36. Rezaian M, Hoshyar H. Human infection with *Cyclospora cayentensis*: report of a case. *Hakim J* 2000; 3: 39-43.
37. Rafiei A, Sadat Roointan E, Samarbaf-Zadeh AR, Shayesteh AA. Genotype analysis of giardia lamblia isolated from children in Ahvaz, southwest of Iran. *Jundishapur Journal of Microbiology* 2013; 6: 279-283.
38. Asher AJ, Holt DC, Andrews RM, Power ML. Distribution of *Giardia duodenalis* assemblages A and B among children living in a remote indigenous community of the Northern Territory, Australia. *PLoS One* 2014; 9: e112058. DOI: 10.1371/journal.pone.0112058.
39. de Quadros RM, Weiss PH, Marques SM, Miletti LC. Potential cross-contamination of similar *Giardia duodenalis* assemblage in children and pet dogs in Southern Brazil, as determined by PCR-RFLP. *Rev Inst Med Trop Sao Paulo* 2016; 58: 66. DOI: 10.1590/S1678-9946201658066.
40. Pestechian N, Rasekh H, Rostami-Nejad M, Yousofi HA, Hosseini-Safa A. Molecular identification of *Giardia lamblia*; is there any correlation between diarrhea and genotyping in Iranian population? *Gastroenterol Hepatol Bed Bench* 2014; 7: 168-172.
41. García-Cervantes PC, Báez-Flores ME, Delgado-Vargas F, Ponce-Macotela M, Nawa Y, de-la-Cruz Md-C, et al. *Giardia duodenalis* genotypes among schoolchildren and their families and pets in urban and rural areas of Sinaloa, Mexico. *J Infect Dev Ctries* 2017; 11: 180-187.
42. Anuar TS, Mokhtar N, Salleh FM, Al-Mekhlafi HM. Human giardiasis in malaysia: correlation between the presence of clinical manifestation and *Giardia intestinalis* assemblage. *Southeast Asian J Trop Med Public Health* 2015; 46: 835-843.
43. Carvalho TB, Carvalho LR, Mascarini LM. Occurrence of enteroparasites in day care centers in Botucatu (São Paulo State, Brazil) with emphasis on *Cryptosporidium* sp., *Giardia duodenalis* and *Enterobius vermicularis*. *Rev Inst Med Trop Sao Paulo* 2006; 48: 269-273.
44. Feng Y, Xiao L. Zoonotic potential and molecular epidemiology of *Giardia* species and giardiasis. *Clin Microbiol Rev* 2011; 24: 110-140.
45. Khabisi SA, Najafi AN, Khorashad AS. Molecular diagnosis of intestinal microsporidia infection in HIV/AIDS-patients in Zahedan city, Southeast of Iran. *Ann Parasitol* 2022; 68: 87-92.
46. Çetinkaya Ü, Caner A. Prevalence of microsporidiosis in different hosts in Turkey: a meta-analysis. *Turkiye Parazitoloj Derg* 2020; 44: 232-238.
47. Mahdi NK, Al-Saadoon MA. Microsporidiosis among children with malignant diseases in Basrah, Iraq. *Pak J Med Sci* 2012; 28: 621-624.
48. Mohraz M, Rezaeian M, Vaziri S, Zali MR, Jafari MA, Memar AR, et al. Prevalence of intestinal parasitic pathogens among HIV-positive individuals in Tehran Andkermansha. *Res Med* 2004; 28: 303-306.
49. Heydari A, Hatam G, Fouladvand M, Sadjjadi SM, Barazesh A. Investigating the prevalence of intestinal parasites in immunocompromised patients in Bushehr province, Southwest Iran: a conventional and molecular study. *Turkiye Parazitoloj Derg* 2021; 45: 121-127.
50. Falahi S, Badparva E, Nahravanian H, Chegeni SA, Ebrahimzadeh F. Prevalence of intestinal parasites in HIV+ and AIDS patients Khorramabad 2006. *Yafte* 2007; 9: 39-45.
51. Berenji F, Sarvghad MR, Fata AM, Hosseini-nejad Z, Saremi E, Ganjbakhsh M, Izadi Jahanparvar R. A study of the prevalence of intestinal parasitic infection in HIV positive individuals in Mashhad, Northeast Iran. *Jundishapur J Microbiol* 2010; 3: 61-65.
52. Nahrevanian H, Assmar M. A case report of Cryptosporidiosis and Isosporiasis in AIDS patients in Iran. *J Trop Med Parasitol* 2006; 29: 33-36.
53. Adarvishi S, Asadi M, Ghasemi DC, Tavalla M, Hardani F. Prevalence of intestinal parasites in HIV-positive patients attending Ahvaz health centers in 2012: a cross-sectional study in south of Iran. *Jundishapur J Chronic Dis Care* 2016; 5: e24895. DOI: 10.17795/jjcdc-24895.
54. Rasti S, Hassanzadeh M, Hooshyar H, Momen-Heravi M, Mousavi SG, Abdoli A. Intestinal parasitic infections in different groups of immunocompromised patients in Kashan and Qom cities, central Iran. *Scand J Gastroenterol* 2017; 52: 738-741.
55. Najafi-Asl M, Teshnizi SH, Davoodian P, Sharifi-Sarasiabi K. Cryptosporidiosis in HIV-positive patients, Bandar Abbas, Iran: a cross-sectional study. *Hormozgan Medical Journal* 2020; 24: e99375. DOI: 10.5812/hmj.99375.

56. Ghafari R, Rafiei A, Tavalla M, Choghakabodi PM, Nashibi R, Rafiei R. Prevalence of *Cryptosporidium* species isolated from HIV/AIDS patients in southwest of Iran. *Comp Immunol Microbiol Infect Dis* 2018; 56: 39-44.
57. Mirjalali H, Mohebbali M, Mirhendi H, Gholami R, Keshavarz H, Meamar AR, Rezaeian M. Emerging intestinal microsporidia infection in HIV+/AIDS patients in Iran: microscopic and molecular detection. *Iran J Parasitol* 2014; 9: 149-154.
58. Izadi S, Mohaghegh MA, Ghayour-Najafabadi Z, Azami M, Mirzaei F, Namdar F, et al. Frequency and molecular identification of *Cryptosporidium* species among immunocompromised patients referred to hospitals, Central Iran, 2015-16. *Iran J Parasitol* 2020; 15: 31-39.
59. Daryani A, Sharif M, Meigouni M, Mahmoudi FB, Rafiei A, Sh G, et al. Prevalence of intestinal parasites and profile of CD4+ counts in HIV+/AIDS people in north of Iran, 2007-2008. *Pak J Biol Sci* 2009; 12: 1277-1281.
60. Ghobadi H, Moradi G, Mirhadi F, Gharibi F, Gharib A. Prevalence of intestinal parasitic infections in HIV-positive patients in Sanandaj-Kurdistan province-west Iran in 2007-2008. *Life Sci J* 2013; 10 (Suppl IS): 22-24.
61. Ghorbanzadeh B, Sadraie J, Emadi Kuchak H. Diagnosis of *Cryptosporidium* and intestinal Microsporidia in HIV/AIDS patients with staining and PCR methods on 16srRNA gen. *Journal of Arak University of Medical Sciences* 2012; 15: 37-47.
62. Yosefi F, Rahdar M, Alavi SM, Samany A. A study on prevalence of gastrointestinal parasitic infections in HIV(+) patients referred to Ahvaz Razi Hospital in 2008-2009. *Jundishapur J Microbiol* 2012; 5: 424-426.
63. Zali MR, Mehr AJ, Rezaian M, Meamar AR, Vaziri S, Mohraz M. Prevalence of intestinal parasitic pathogens among HIV-positive individuals in Iran. *Jpn J Infect Dis* 2004; 57: 268-270.
64. Srisuphanunt M, Suvedyathavorn V, Suputtamongkol Y, Arnantapunpong S, Wiwanitkit V, Satitvipawee P, Tansupasawadikul S. Potential risk factors for *Cryptosporidium* infection among HIV/AIDS patients in central areas of Thailand. *J Public Health* 2008; 16: 173-182.
65. Agholi M, Hatam GR, Motazedian MH. HIV/AIDS-associated opportunistic protozoal diarrhea. *AIDS Res Hum Retroviruses* 2013; 29: 35-41.
66. Abdi J, Shams M, Visani Y, Karimiyan M, Kenarkoohi A. Prevalence of microsporidia in HIV-infected patients in Iran: a meta-analysis and systematic review. *Journal of Ilam University of Medical Sciences* 2020; 28: 21-28.
67. Sarkari B, Hosseini G, Motazedian MH, Fararouei M, Moshfe A. Prevalence and risk factors of intestinal protozoan infections: a population-based study in rural areas of Boyer-Ahmad district, Southwestern Iran. *BMC Infect Dis* 2016; 16: 703. DOI: 10.1186/s12879-016-2047-4.
68. Bafghi AF, Afkhami-Ardekani M, Tafti AD. Frequency distribution of intestinal parasitic infections in diabetic patients – Yazd 2013. *Iran J Diabetes Obes* 2015; 7: 33-37.